問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Chia-Yi Christian Hosptal (在職)

Division of Thoracic Medicine

Taipei Veterans General Hospital (在職)

Division of Geriatrics

Division of Family Medicine

更新時間：2023-09-19

林明憲
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

0Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

林明憲

Chia-Yi Christian Hosptal

Division of Thoracic Medicine

List

12Cases

2010-08-30 - 2012-09-30

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2007-11-15 - 2008-06-30

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
24Sites

Terminated23Sites

Study ended1Sites

2011-04-01 - 2012-11-16

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated7Sites

Study ended1Sites

2010-09-01 - 2012-03-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2013-03-01 - 2014-12-31

Phase III

A 26-week multi-center randomized double-blind study to compare efficacy and safety of NVA237 versus placebo as an add-on to maintenance therapy with fixed-dose combination salmeterol/ fluticasone propionate in COPD patients with moderate to severe airflow limitation.

  • Condition/Disease

    COPD

  • Test Drug

    NVA237

Participate Sites
9Sites

Terminated9Sites

2012-06-15 - 2013-02-28

Phase III

A 12-week treatment, randomized, blinded, double-dummy, parallel-group study to assess the efficacy, safety, and tolerability of NVA237 (50 μg o.d.) compared to tiotropium (18 μg o.d.) in patients with chronic obstructive pulmonary disease (COPD)

  • Condition/Disease

    COPD

  • Test Drug

    NVA237

Participate Sites
7Sites

Terminated7Sites

2008-11-16 - 2009-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
13Sites

Not yet recruiting1Sites

Terminated12Sites

2007-05-30 - 2009-06-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2007-09-01 - 2009-03-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Terminated10Sites

2008-12-01 - 2010-11-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

1 2
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB